Skip to content
Search

Latest Stories

Over half a million dementia cases could go undiagnosed by 2040, study predicts

Over half a million dementia cases could go undiagnosed by 2040, study predicts

Currently, an estimated 850,000 people are living with dementia in the UK, with 315,000 undiagnosed cases

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted.


The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is “no progress in improving diagnosis rates.”

At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed.

Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations.  Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.

Richard Sloggett, programme director at the Future Health Research Centre and report author said: “Progress is being made on increasing dementia diagnosis rates, but this research shows that business as usual will not deliver what patients need.”

“The expected significant increase in dementia cases means that without investment in increased diagnostic capacity and capability more and more people will have undiagnosed dementia and be unable to access the treatment and care that they need.

“The publication of system readiness plans for new treatments coupled with new diagnosis targets backed up with investment in diagnostics and incentives should be a priority for each government of the four UK nations,” he added.

The research explored three different scenarios for the trajectory of dementia diagnosis rates up to 2040.

If the diagnosis rates in 2040 were to remain unchanged from present levels across all four UK nations, it's projected that over 565,000 individuals – nearly a quarter of a million more than today – would have dementia without a diagnosis.

If all UK nations were to achieve the two-thirds target set in England, there would be a smaller but still significant increase of 175,000 undiagnosed cases, bringing the total to 490,000 cases.

Only when all four nations significantly boost diagnosis rates to 80 per cent, there would be a decrease in the overall number of undiagnosed individuals with dementia by 2040. However, even in this scenario, nearly 300,000 cases of undiagnosed dementia would persist, the study predicted.

To tackle low diagnosis rates, the report suggested setting of new, more ambitious dementia diagnosis targets, along with the introduction of financial incentives to support their delivery.

Laura Steele, president and general manager of Lilly UK, also exphasised the need to improve diagnostic capabilities to “tackle inequalities in diagnosis rates and ensure people can access the right care and support.”

The study underscored the importance of timely and accurate diagnosis to enable dementia patients to access the care and support they need, as well as gain benefit from the potential arrival of new treatments.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less